Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 0.86 Billion |
| Market Size (2029) | USD 2.07 Billion |
| CAGR (2024 - 2029) | 19.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Analysis
The Viral Vector Contract Development And Manufacturing Organization Market size is estimated at USD 0.86 billion in 2024, and is expected to reach USD 2.07 billion by 2029, growing at a CAGR of 19% during the forecast period (2024-2029).
Some of the key factors driving market growth include programs launched by key players in viral vector development and increasing investments by the government to create innovative technologies and manufacturing facilities.
Contract manufacturers are actively building up their capabilities as the biopharma industry suffers from a severe lack of viral vectors for cell and gene therapies. In March 2023, Sartorius agreed to acquire French startup Polyplus for EUR 2.4 billion (USD 2.6 billion). This indicates the biopharma industry’s increasing investments in cell and gene therapy production. Such activities in the CDMO space are expected to fuel market growth in the coming years.
According to the study published in the Radiology and Oncology Journal in February 2022, the use of viral vectors to treat cancer has the potential to change the area of oncology. Virus vectors, in particular, provide a unique mix of effective gene delivery and immune system engagement for anti-tumour responses. Such studies are expected to lead to the increased adoption of viral vector manufacturing in designing therapies for cancer, driving market growth.
However, challenges associated with the viral vector contract development and manufacturing, along with high costs, are some factors expected to hinder the market’s growth in the long run.
Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Trends
Adeno-Associated Virus is Expected to Witness a Strong Growth During the Forecast Period
Adeno-associated virus is one of the rapidly growing segments in the market. The major factors contributing to segmental growth include the high focus of the companies on the development of gene therapies and the rising investments.
In October 2022, Astellas made a USD 50 million investment in Taysha Gene Therapies Inc. to gain access to two of its adeno-associated virus (AAV) gene therapy initiatives for Rett syndrome and giant axonal neuropathy (GAN). Similarly, the National Cancer Institute (NIC), based on data from March 2022, was given USD 6.9 billion by the Consolidated Appropriations Act 2022. This was a net increase of USD 353 million over FY 2021. The FY 2022 allocation included USD 194 million in funding for the Cancer Moonshot and USD 50 million for the Childhood Cancer Data Initiative. Thus, increasing investments in enabling a precision medicine approach is expected to drive the market’s growth during the forecast period.
In December 2022, Merck signed a memorandum of understanding (MoU) with Synplogen, a start-up founded by Kobe University's Graduate School of Science, Technology, and Innovation. Merck’s Millipore Contract Testing Development and Manufacturing Organization (CTDMO) and Synplogen will integrate their capabilities to provide streamlined development, manufacturing, and testing for viral vector gene therapies in Japan. In August 2022, Polyplus, an upstream solutions provider for advanced biologic and cell and gene therapy production, launched its new Transgene Plasmid Engineering Services for viral vector manufacturing. The expansion of plasmid services can be used as a standalone or a complement to the industry standard PEIpro and FectoVIR-AAV reagents and kits for next-generation viral vector and gene therapy manufacturing.
The key factors driving the growth of the adeno-associated virus CDMO segment include the increasing use of gene therapy, advancements in AAV vectors, and rising outsourcing of AAV vector manufacturing. For instance, in November 2022, Thermo Fisher Scientific introduced the Gibco CTS adeno-associated virus (AAV) MAX Helper Free production system, which can save time and reduce costs by 50%. The CTS AAV-MAX system includes several components, such as mammalian cells, a cell culture medium, a transfection kit, and a buffer.
Therefore, owing to the high investment and increasing focus on AAV, the segment is believed to witness significant growth during the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
The market for viral vector CDMO is expected to witness significant growth in the coming years. The United States is expected to hold a significant share of the North American market for viral vector CDMO. This is primarily due to the growing disease burden and the established biotech industry focusing on gene therapy development and advancements.
The funding for viral vector manufacturing is increasing, which is benefiting the market. For instance, in January 2023, Vector BioMed received funding of USD 15 million in the first round to help fill a big gap in manufacturing cell and gene therapies. Vector BioMed is an emerging company in the viral vector CDMO space.
In April 2023, VintaBio announced that it received USD 64 million in funding for the establishment of the new CDMO in Philadelphia. The new CDMO focuses on producing viral vectors. VintaBio manufactures AAV and lentiviral vectors for companies pursuing clinical development of cell and gene therapies.
The above-mentioned developments indicate that rising funding for viral vector CDMOs is one of the major factors contributing to the market expansion in the region.
Viral Vector Contract Development and Manufacturing Organization (CDMO) Industry Overview
The viral vector CDMO market is moderately competitive and consists of several players globally. Companies are focusing more on receiving funding for manufacturing needs. Some of the key players operating in the market include ThermoFisher Scientific, Charles River Laboratories International, Inc., Catalent Inc., Creative Biogene, and Lonza.
Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Leaders
-
ThermoFisher Scientific
-
Lonza
-
Catalent Inc.
-
Creative Biogene
-
Charles River Laboratories International, Inc.
*Disclaimer: Major Players sorted in no particular order
Viral Vector Contract Development and Manufacturing Organization (CDMO) Market News
- March 2024: Charles River Laboratories International Inc. and Navega Therapeutics Inc. entered into an agreement for the production of AAV9. Under Charles River's Cell and Gene Therapy Accelerator Program (CAP), Navega will utilize the company's CDMO capabilities and advisory services for the production of NT-Z001, an AAV-based gene therapy.
- May 2023: AGC Biologics, a viral vector CDMO, launched BravoAAV and ProntoLVV viral vector platforms. AGC Biologics has over three decades of experience in Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing, and analytics.
Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Programs by the Companies for Viral Vector Production
4.2.2 Government Support For Viral Vector CDMOs
4.3 Market Restraints
4.3.1 Challenges Faced By CDMOs
4.3.2 High Cost Associated With CDMO Establishment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size - Value in USD)
5.1 By Vector Type
5.1.1 Adenovirus
5.1.2 Retrovirus
5.1.3 Adeno-Associated Virus
5.1.4 Lentivirus
5.1.5 Others
5.2 By Workflow
5.2.1 Upstream Manufacturing
5.2.2 Downstream Manufacturing
5.3 By Application
5.3.1 Antisense & RNAi Therapy
5.3.2 Gene Therapy
5.3.3 Cell Therapy
5.3.4 Vaccinology
5.3.5 Other Applications
5.4 By End User
5.4.1 Pharmaceutical & Biopharmaceutical Companies
5.4.2 Academic and Research Institutes
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Oxford Biomedica
6.1.2 Charles River Laboratories Inc.
6.1.3 GeneScript ProBio
6.1.4 Creative Biogene
6.1.5 FUJIFILM Diosynth Biotechnologies
6.1.6 Lonza
6.1.7 Catalent Inc.
6.1.8 Merck KGaA
6.1.9 Curia Global Inc.
6.1.10 Takara Bio Inc.
6.1.11 Thermo Fisher Scientific Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Viral Vector Contract Development and Manufacturing Organization (CDMO) Industry Segmentation
Viral vector CDMOs are contract manufacturing and development organizations specializing in viral vector product manufacturing, which has wide applications across various disease areas, including cancer and infectious diseases.
The viral vector CDMO market is segmented by culture type, application, end user, and geography. By workflow, the market is segmented into upstream processing and downstream processing. By culture type, the market is segmented into adherent culture and suspension culture. By application, the market is segmented into cell & gene therapy development, vaccine development, biopharmaceutical & pharmaceutical discovery, and biomedical research. By end user, the market is segmented into pharmaceutical & biopharmaceutical companies and academic & research institutes. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for all the above segments.
| By Vector Type | |
| Adenovirus | |
| Retrovirus | |
| Adeno-Associated Virus | |
| Lentivirus | |
| Others |
| By Workflow | |
| Upstream Manufacturing | |
| Downstream Manufacturing |
| By Application | |
| Antisense & RNAi Therapy | |
| Gene Therapy | |
| Cell Therapy | |
| Vaccinology | |
| Other Applications |
| By End User | |
| Pharmaceutical & Biopharmaceutical Companies | |
| Academic and Research Institutes |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Research FAQs
How big is the Viral Vector Contract Development And Manufacturing Organization Market?
The Viral Vector Contract Development And Manufacturing Organization Market size is expected to reach USD 0.86 billion in 2024 and grow at a CAGR of 19% to reach USD 2.07 billion by 2029.
What is the current Viral Vector Contract Development And Manufacturing Organization Market size?
In 2024, the Viral Vector Contract Development And Manufacturing Organization Market size is expected to reach USD 0.86 billion.
Who are the key players in Viral Vector Contract Development And Manufacturing Organization Market?
ThermoFisher Scientific, Lonza, Catalent Inc., Creative Biogene and Charles River Laboratories International, Inc. are the major companies operating in the Viral Vector Contract Development And Manufacturing Organization Market.
Which is the fastest growing region in Viral Vector Contract Development And Manufacturing Organization Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Viral Vector Contract Development And Manufacturing Organization Market?
In 2024, the North America accounts for the largest market share in Viral Vector Contract Development And Manufacturing Organization Market.
What years does this Viral Vector Contract Development And Manufacturing Organization Market cover, and what was the market size in 2023?
In 2023, the Viral Vector Contract Development And Manufacturing Organization Market size was estimated at USD 0.70 billion. The report covers the Viral Vector Contract Development And Manufacturing Organization Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Viral Vector Contract Development And Manufacturing Organization Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Viral Vector Contract Development and Manufacturing Organization (CDMO) Industry Report
Statistics for the 2024 Viral Vector Contract Development And Manufacturing Organization (CDMO) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Viral Vector Contract Development And Manufacturing Organization (CDMO) analysis includes a market forecast outlook for 2024 to (2024to2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Report Snapshots
- Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Size
- Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Share
- Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Trends
- Viral Vector Contract Development and Manufacturing Organization (CDMO) Companies
